Hemostatic sponge for complex tissue injury as well as preparation method and application of hemostatic sponge
By constructing amorphous calcium phosphate crystal chains on a silk fibroin matrix, the problem of combining biocompatibility and mechanical properties of existing materials has been solved, achieving a highly efficient hemostatic effect on soft and hard tissue injuries.
Patent Information
- Application Number
- CN202411173123.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-26
AI Technical Summary
Existing hemostatic materials cannot effectively control bleeding in complex tissue injuries, especially those involving the combination of soft and hard tissues, while ensuring biocompatibility and biodegradability.
Using silk fibroin as an organic matrix and combining it with amorphous calcium phosphate oligomers, a hemostatic sponge with critical-sized calcium phosphate crystal chains is constructed through self-assembly. Combining the biofunctionality of silk fibroin with the mechanical strength of calcium phosphate, a hemostatic material that can adapt to different tissue characteristics is prepared.
It significantly improves the mechanical strength and shape adaptability of hemostatic sponges, better meeting the hemostasis needs of soft and hard tissues, reducing bleeding volume and bleeding time, and possessing excellent biocompatibility and biodegradability.
Smart Images

Figure CN119015482A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedical materials, and in particular to a hemostatic sponge for complex tissue damage and a preparation method and application thereof. Background Art
[0002] Accidental trauma, such as collisions, crush injuries, gunshots or stabbings, often results in severe tissue loss with tissue exposure, which in turn leads to uncontrolled bleeding in the defect cavity. Although the body's coagulation system is activated immediately after the injury, it is difficult to quickly form a stable blood clot to stop bleeding in the tissue defect cavity, especially when there is continuous bleeding. Uncontrolled continuous bleeding often leads to serious consequences such as hypotension, shock, and even death.
[0003] In clinical treatment, compression of the bleeding site is the main strategy for controlling bleeding. However, for some bleeding occurring in tissue defect cavities, traditional hemostatic methods (such as pressing, gauze, tourniquets, etc.) often cannot effectively compress the damaged blood vessels in the defect cavity, resulting in poor hemostatic effects. Therefore, for these non-compressible bleeding in tissue defect cavities, hemostatic materials must be able to absorb bleeding and fill the defect cavity, provide sufficient compression force on the damaged blood vessels in the cavity, and thus achieve the purpose of controlling bleeding. Recently, many expandable hemostatic sponges have been developed for non-compressible bleeding in soft tissues, such as femoral artery injury and liver penetrating injury. The compression effect of the expandable hemostatic sponge on the bleeding point of soft tissue after blood absorption and collision can effectively stop bleeding, providing an ideal strategy for hemostatic treatment in tissue defect cavities.
[0004] In real clinical trauma cases, the cavities produced by tissue defects are often more complex. Both soft and hard tissues of the body may be exposed, resulting in tissue damage and cavities. In addition, there are great differences in the shape of the cavity and the type of damaged blood vessels. These characteristics require that the ideal hemostatic sponge needs to be able to adapt to different cavity shapes, different bleeding behaviors, and different tissue mechanical properties. For example, soft tissues (such as the liver) have a certain degree of deformability and are rich in blood vessels. Soft tissue defects often lead to a large amount of bleeding, which requires the hemostatic sponge to quickly absorb blood and fill the defect cavity. In addition, since soft tissues have a certain degree of deformability, the hemostatic sponge must have sufficient compressive force to fix it in the soft tissue defect to compress the bleeding point, especially when there is a large amount of bleeding. Hard tissues (such as the tibia) are rigid matrices with a large number of capillaries. In contrast to soft tissues, hemostasis of hard tissue defects requires a hemostatic sponge that can adapt to the shape of the defect cavity while providing high compressive force, which can effectively control the continuous bleeding in the damaged capillaries. Therefore, a promising hemostatic sponge should have both high mechanical strength and high deformability to adapt to the bleeding characteristics of soft tissue defects and hard tissue defects to achieve hemostatic treatment of complex tissue defect bleeding.
[0005] However, it is very challenging to integrate high mechanical strength and high deformability in one material, especially under the premise of ensuring the biocompatibility and biodegradability of the material. Materials with good biocompatibility and biodegradability are usually organic polymers with excellent deformability and relatively weak mechanical strength. Currently, the main method for enhancing the mechanical properties of materials is to composite inorganic nanomaterials with organic polymers, with the aim of combining the high mechanical strength of inorganic materials with the deformability of organic polymers. However, the inherent hard / brittle properties of inorganics and the inherent soft / deformable properties of polymers make it difficult to integrate high mechanical strength and deformability in one composite material. The two contradictory properties of mechanical strength and deformability make the integration of the two a technical challenge for organic-inorganic composite materials.
[0006] Publication No. CN115487345A discloses a hemostatic hydrogel and hemostatic sponge based on silk fibroin, and a preparation method and application thereof, wherein lauroyl arginine ethyl ester hydrochloride and a silk fibroin solution are vortex-mixed, and the mixed solution is heated to induce rapid gelation of the silk fibroin, a large number of bubbles are fixed in the rapidly gelling hydrogel, and further freeze-dried to obtain a hemostatic sponge with high liquid absorption rate and asymmetric pores. However, the hemostatic sponge is only suitable for hemostasis of soft tissue injuries, and cannot meet the needs of bleeding caused by hard tissue injuries.
[0007] Publication No. CN116785491A discloses a porous composite hemostatic sponge and a preparation method thereof, which mainly includes silk fibroin, sodium alginate, dopamine hydrochloride and a crosslinking agent, and the above components are evenly mixed by a simple "one-pot method" and then crosslinked by calcium ions. However, the porous composite hemostatic sponge uses the catechol part in dopamine to combine with the amino group or thiol group in the tissue to give sodium alginate excellent adhesion to the tissue, but the enhanced adhesion is a disadvantage when the hemostatic material needs to be removed. Summary of the invention
[0008] In order to solve the above technical problems, the present invention provides a method for preparing a hemostatic sponge for complex tissue damage. The preparation method does not require complex machines, has a simple process, and is low in cost, and has broad application prospects in the field of trauma hemostasis.
[0009] A method for preparing a hemostatic sponge for complex tissue damage comprises the following steps:
[0010] (1) boiling the washed silk cocoons with a sodium carbonate solution for degumming;
[0011] (2) dissolving the silkworm cocoons treated in step (1) in a lithium bromide solution, dialyzing for desalination, then centrifuging and discarding the precipitate, and heating and concentrating the supernatant to obtain a silk fibroin solution;
[0012] (3) adding triethylamine to the ethanol solution of calcium chloride under stirring, then dropping the ethanol solution of phosphoric acid, centrifuging, and resuspending with ethanol to obtain a calcium phosphate oligomer solution;
[0013] (4) centrifuging the calcium phosphate oligomer solution obtained in step (3), washing, resuspending, and evenly mixing with the silk fibroin solution obtained in step (2), and incubating at room temperature to obtain a hemostatic sponge precursor solution;
[0014] (5) The hemostatic sponge precursor solution obtained in step (4) is frozen, annealed at low temperature, thawed at room temperature, then freeze-dried, and sterilized by irradiation to obtain a hemostatic sponge for complex tissue damage.
[0015] The present invention uses silk fibroin as the organic matrix of the organic-inorganic hybrid sponge, and can obtain a silk fibroin solution with complete structure and good biocompatibility through degumming, dissolving and concentrating; and uses amorphous calcium phosphate oligomers as the inorganic component of the organic-inorganic hybrid sponge, and obtains nano-sized amorphous calcium phosphate oligomers under the end-capping effect of triethylamine. The self-assembly mechanism between the amorphous calcium phosphate oligomers and the silk fibroin matrix is utilized to construct a critical size calcium phosphate with unique mechanical properties on the silk fibroin matrix, and the excellent biological functionality and biocompatibility of the silk fibroin matrix and the good mechanical strength, deformability and coagulation-promoting ability of the critical size calcium phosphate promote the mechanical properties, shape adaptability and hemostatic ability of the hemostatic sponge.
[0016] Preferably, in step (1), the bath ratio of the silkworm cocoons to the sodium carbonate solution is 10:2-3 g / L, and the concentration of the sodium carbonate solution is 0.01-0.03M.
[0017] Sodium carbonate solution is a commonly used degumming solution that can remove sericin from silk cocoons and has good biocompatibility.
[0018] Preferably, in step (2), the bath ratio of the treated silkworm cocoons to the lithium bromide solution is 2:10-15 g / mL, and the concentration of the lithium bromide solution is 9-10 M.
[0019] The present invention adopts lithium bromide solution to dissolve silk fibroin. This method allows most of the inorganic salt ions to enter the interior of the silk fibroin, cuts off most of the original hydrogen bonds and shears the silk fibroin so that it is fully dissolved, avoiding the problem of instability of the silk fibroin aqueous solution caused by dissolution in a mild environment.
[0020] Preferably, in step (2), the concentration of the silk fibroin solution is 80-100 mg / mL.
[0021] Preferably, in step (3), the molar ratio of phosphoric acid to calcium chloride is 3:3-5.
[0022] In step (3), the preferred ratio of calcium chloride to phosphoric acid can adjust the product to amorphous calcium phosphate, and the hydrogen atoms in the triethylamine molecules preferentially bind to the oxygen atoms in the calcium phosphate oligomer monomers through hydrogen bonds, so that the calcium phosphate monomers will not polymerize, thereby obtaining nano-sized calcium phosphate oligomers. The amount of hydrogen ions is calculated based on the amount of phosphoric acid added, thereby determining the amount of triethylamine added.
[0023] Preferably, in step (3), the concentration of the calcium phosphate oligomer solution is 4-6 mg / mL.
[0024] Preferably, in step (4), in the hemostatic sponge precursor solution, the mass ratio of the silk fibroin to the calcium phosphate oligomer is 1:4-15.
[0025] When the ratio is within the above range, calcium phosphate oligomers can be fully assembled under the regulation of silk fibroin to obtain a hemostatic sponge precursor solution.
[0026] Preferably, in step (5), the low-temperature annealing temperature is -4 to -8°C and the time is 24-72 hours.
[0027] Low-temperature annealing can reduce the problem of uneven crystal size during the freezing process, and at the same time, it can allow the hemostatic sponge precursor liquid to fully self-assemble, thereby obtaining a hemostatic sponge with a porous structure, good mechanical properties, and deformability.
[0028] The present invention also provides a hemostatic sponge for complex tissue damage prepared by the above preparation method, which has excellent mechanical properties and deformability, and has excellent biocompatibility and hemostatic properties in vivo and in vitro.
[0029] The present invention also provides the use of the above-mentioned hemostatic sponge in the preparation of soft and hard tissue injury hemostatic materials. By combining critical size calcium phosphate oligomers with a silk fibroin matrix, the mechanical strength and shape adaptability of the hemostatic sponge are significantly improved, so that it can better meet the needs of soft and hard tissue hemostasis, and provide a biomedical composite material for the treatment of complex tissue injury bleeding.
[0030] Compared with the prior art, the beneficial effects achieved by the present invention are:
[0031] 1. The present invention prepares a hemostatic sponge by combining a critical-size calcium phosphate crystal chain with a silk fibroin matrix. The excellent biofunctionality and biocompatibility of the silk fibroin matrix and the good mechanical strength, deformability and coagulant ability of the critical-size calcium phosphate significantly improve the mechanical strength and shape adaptability of the hemostatic sponge after the two are combined.
[0032] 2. The hemostatic sponge prepared by the present invention can better meet the needs of soft tissue and hard tissue hemostasis, significantly reduce the total bleeding volume and bleeding time of two bleeding models, and provide a biomedical composite material for complex tissue injury hemostasis.
[0033] 3. The preparation method provided by the present invention does not require complicated machines, has a simple process, and is low in cost, and has broad application prospects in the field of trauma hemostasis. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 The internal structure analysis diagram of the hemostatic sponge prepared in Example 1, wherein:
[0035] A is a schematic diagram of the self-assembly of silk fibroin and calcium phosphate oligomers;
[0036] B is the Fourier transform infrared spectra of the hemostatic sponge and hydroxyapatite prepared in Example 1 and Comparative Example 2;
[0037] C is the thermogravimetric analysis diagram of the hemostatic sponge prepared in Example 1 and Comparative Example 2;
[0038] D is a high-resolution transmission electron micrograph of the hemostatic sponge precursor solution prepared in Example 1;
[0039] E is the statistical result of the length and width of the calcium phosphate crystal chain in the hemostatic sponge precursor solution prepared in Example 1;
[0040] F is the XRD spectrum of the hemostatic sponge and the simulated calcium phosphate crystal chain prepared in Example 1 and Comparative Example 1;
[0041] G is a three-dimensional structure diagram of the simulated calcium phosphate crystal chain;
[0042] H is a high-resolution transmission electron microscopy image of calcium phosphate crystal chains with different bending curvatures;
[0043] I is a statistical diagram showing the relationship between bending energy and bending angle in calcium phosphate crystal chains of different thicknesses;
[0044] J is the relationship between the maximum bending energy and the maximum bending angle in calcium phosphate crystal chains of different thicknesses;
[0045] K is the relationship between the bending energy and the bending angle in a single calcium phosphate crystal chain with a thickness of 1.9 nm.
[0046] Figure 2 The figure is an analysis diagram of the mechanical properties and liquid absorption performance of the hemostatic sponge prepared in Example 1, wherein:
[0047] A is a macroscopic image of the hemostatic sponge prepared in Example 1;
[0048] B is the stress-strain curve of the hemostatic sponge prepared in Example 1 and Comparative Examples 1-2;
[0049] C is a stress comparison diagram of the hemostatic sponges prepared in Example 1 and Comparative Examples 1-2 when the strain is 60%;
[0050] D is a comparison chart of the elastic modulus of the hemostatic sponges prepared in Example 1 and Comparative Examples 1-2;
[0051] E is a comparison diagram of the water absorption process of the hemostatic sponges prepared in Example 1 and Comparative Examples 1-2;
[0052] F is a comparison chart of the deformation recovery rates of the hemostatic sponges prepared in Example 1 and Comparative Examples 1-2;
[0053] G is a comparison chart of the liquid absorption rates of the hemostatic sponges prepared in Example 1 and Comparative Examples 1-2.
[0054] Figure 3 This is an analysis diagram of the adaptability of the hemostatic sponge prepared in Example 1 to filling of different shapes, wherein:
[0055] A and B are the spatial filling effect diagram and the local spatial fitting rate statistical diagram of the hemostatic sponge prepared in Example 1 and Comparative Examples 1-2 in a mold with smooth edges, respectively;
[0056] C and D are the spatial filling effect diagram and the local spatial fitting rate statistical diagram of the hemostatic sponge prepared in Example 1 and Comparative Example 1-2 in the sharp-edge mold, respectively;
[0057] E and F are optical microscope pictures of the hemostatic sponge prepared in Example 1 in a sharp-edge mold at magnifications of 50 times and 200 times, respectively.
[0058] Figure 4 The figure is a diagram showing the hemostatic effect of the hemostatic sponge prepared in Example 1 in a rat liver penetrating wound bleeding model, wherein:
[0059] A is a schematic diagram of the hemostasis process of the rat liver penetrating wound bleeding model.
[0060] B is a diagram showing the hemostatic process of the blank group, gauze group, gelatin sponge group, and the hemostatic sponge group prepared in Example 1 and Comparative Examples 1-2;
[0061] C is the hemostatic endpoint graph of the blank group, gauze group, gelatin sponge group, and the hemostatic sponge group prepared in Example 1 and Comparative Examples 1-2;
[0062] D and E are statistical graphs of total bleeding volume and hemostasis time of the blank group, gauze group, gelatin sponge group, and hemostatic sponge groups prepared in Example 1 and Comparative Examples 1-2, respectively.
[0063] Figure 5 The figure is a diagram showing the hemostatic effect of the hemostatic sponge group prepared in Example 1 on the penetrating wound of the tibia of rats, wherein:
[0064] A is a schematic diagram of the hemostasis process of the rat tibial penetrating wound non-compressible bleeding model;
[0065] BG are the hemostatic process diagrams of the blank group, gauze group, gelatin sponge group, and the hemostatic sponge groups prepared in Example 1 and Comparative Examples 1-2;
[0066] H and I are the statistical graphs of total bleeding volume and hemostasis time of the blank group, gauze group, gelatin sponge group, and the hemostatic sponge groups prepared in Example 1 and Comparative Examples 1-2, respectively.
[0067] Figure 6The in vivo degradation performance and biosafety of the hemostatic sponge group prepared in Example 1, wherein:
[0068] A is a graph showing the degradation of the hemostatic sponge prepared in Example 1 after subcutaneous implantation for 7, 14, and 28 days;
[0069] B is the HE staining result of the main organs of rats after the hemostatic sponge prepared in Example 1 was subcutaneously implanted for 28 days;
[0070] CE are respectively the blood routine test results of rats 28 days after the hemostatic sponge prepared in Example 1 was subcutaneously implanted;
[0071] FG are the liver function results of rats after the hemostatic sponge prepared in Example 1 was subcutaneously implanted for 28 days.
[0072] Figure 7 The mechanical properties, liquid absorption properties and hemostatic effect of the hemostatic sponge prepared in Example 2 are as follows:
[0073] A is a stress comparison diagram of the hemostatic sponge prepared in Example 2 and Comparative Example 2 when the strain is 60%;
[0074] B is a comparison chart of the elastic modulus of the hemostatic sponge prepared in Example 2 and Comparative Example 2;
[0075] C is a comparison chart of the deformation recovery rates of the hemostatic sponges prepared in Example 2 and Comparative Example 2;
[0076] D is a comparison chart of the liquid absorption rates of the hemostatic sponges prepared in Example 2 and Comparative Example 2;
[0077] E and F are endpoint diagrams of hemostasis of soft tissue injury obtained by the hemostatic sponge of Example 2 and Comparative Example 2, respectively;
[0078] G and H are statistical diagrams of the total bleeding volume and hemostasis time of the hemostatic sponges prepared in Example 2 and Comparative Example 2 in hemostasis of soft tissue injuries;
[0079] I and J are process diagrams of hemostatic sponges prepared in Example 2 and Comparative Example 2 for hemostasis of hard tissue injury, respectively;
[0080] K and L are respectively the statistical graphs of the total bleeding volume and the hemostasis time of the hemostatic sponges prepared in Example 2 and Comparative Example 2 in hemostasis of hard tissue injuries. DETAILED DESCRIPTION
[0081] The present invention will be further described in detail below in conjunction with the examples, but the embodiments of the present invention are not limited to the following examples.
[0082] The raw materials used in the present invention are all commercially available.
[0083] Example 1
[0084] (1) Take 20 g of silkworm cocoons and cut them into pieces. Rinse them three times with deionized water. Boil the cocoons with 5 L of 0.02 M sodium carbonate solution for 30 min, rinse with deionized water, and dry overnight.
[0085] (2) 8 g of the dried sample was placed in 50 mL of 9.3 M lithium bromide solution at 60°C for 4 h. The dissolved solution was transferred to a dialysis bag and dialyzed with deionized water for 72 h, with the solution changed every 8 h. The dialyzed solution was centrifuged at 9000 rpm for 20 min twice to remove the precipitate in the solution, and then concentrated at 45°C for 8 h to obtain a silk fibroin solution (80 mg / mL), which was stored at 4°C for later use.
[0086] (3) 5.88 g of calcium chloride dihydrate was dissolved in 800 mL of ethanol. Under magnetic stirring at 800 rpm, 110.9 mL of triethylamine was added to the above solution. Then, an ethanol solution of phosphoric acid (2.09 mL of phosphoric acid dissolved in 40 mL of ethanol) was added dropwise and stirred. The mixture was centrifuged and the supernatant was discarded. The mixture was washed and resuspended with ethanol to obtain a calcium phosphate oligomer solution (4 mg / mL).
[0087] (4) 50 mL of the resuspended calcium phosphate oligomer solution was washed with deionized water and centrifuged twice, and deionized water was added to adjust the volume to 7.5 mL. Subsequently, 12.5 mL of the silk fibroin solution was added and mixed and stirred at room temperature, and incubated for 1 hour to obtain a hemostatic sponge precursor solution.
[0088] (5) The precursor solution was placed in a -80°C refrigerator and frozen for 40 min, transferred to a -6°C low-temperature constant temperature water bath, annealed at low temperature for 48 h, thawed and freeze-dried at room temperature, and sterilized by radiation to obtain a hemostatic sponge (SF-C).
[0089] Example 2
[0090] The hemostatic sponge (SF-LC) was prepared in the same manner as in Example 1, except that in step (4), 25 mL of the resuspended calcium phosphate oligomer solution was added.
[0091] Comparative Example 1
[0092] (1) Take 20 g of silkworm cocoons and cut them into pieces. Rinse them three times with deionized water. Boil the cocoons with 5 L of 0.02 M sodium carbonate solution for 30 min, rinse with deionized water, and dry overnight.
[0093] (2) 8 g of the dried sample was placed in 50 mL of 9.3 M lithium bromide solution at 60°C for 4 h. The dissolved solution was transferred to a dialysis bag and dialyzed with deionized water for 72 h, with the solution changed every 8 h. The dialyzed solution was centrifuged at 9000 rpm for 20 min twice to remove the precipitate in the solution, and then concentrated at 45°C for 8 h to obtain a silk fibroin solution (80 mg / mL), which was stored at 4°C for later use.
[0094] (3) After 200 mg of hydroxyapatite particles were placed in 7.5 mL of deionized water, 12.5 mL of silk fibroin solution (80 mg / mL) was added to 20 mL, mixed and stirred evenly at room temperature, and incubated for 1 h to obtain a hemostatic sponge precursor solution.
[0095] (4) The hemostatic sponge precursor solution was placed in a -80°C refrigerator and frozen for 40 minutes, transferred to a -6°C low-temperature constant temperature water bath, annealed at low temperature for 48 hours, thawed and freeze-dried at room temperature, and sterilized by radiation to obtain a hemostatic sponge (SF-C).
[0096] Comparative Example 2
[0097] The hemostatic sponge (SF) was prepared in the same manner as in Comparative Example 1, except that in step (3), no nano-hydroxyapatite particles were contained.
[0098] Experimental Example 1: Performance test of the calcium phosphate crystal chain in the hemostatic sponge (SF-C) prepared in Example 1:
[0099] (1) Figure 1 As shown in the schematic diagram A, in the SF-C hemostatic sponge precursor solution, silk fibroin and calcium phosphate oligomers (CPO) are co-assembled to construct a chain of calcium phosphate (CaP) crystal chains; then the length and width of the CaP crystal chains are counted ( Figure 1 E), the results show that its average length is 30nm and its width is 1.8nm.
[0100] (2) The calcium phosphate crystal chains in the SF-C hemostatic sponge prepared in Example 1 and the hydroxyapatite particles (HAP) in the SF-N hemostatic sponge prepared in Comparative Example 1 were subjected to Fourier transform infrared spectroscopy, XRD spectrum, high-resolution transmission electron microscopy analysis and thermogravimetric analysis:
[0101] Figure 1 B is the Fourier transform infrared spectroscopy characterization of SF hemostatic sponge, SF-C hemostatic sponge and hydroxyapatite. The results show that there are certain differences between the calcium phosphate crystal chains of SF-C hemostatic sponge and SF hemostatic sponge and hydroxyapatite containing only silk fibroin.
[0102] Figure 1C is the thermogravimetric analysis result of SF hemostatic sponge and SF-C hemostatic sponge. The results show that as the temperature increases, the mass of SF-C hemostatic sponge still remains 12.7%, which is different from the SF hemostatic sponge containing only silk fibroin. This indicates that the calcium phosphate crystal chain constructed by silk fibroin and calcium phosphate oligomers in the SF-C hemostatic sponge improves the thermal stability of the SF-C hemostatic sponge.
[0103] Figure 1 D is a high-resolution transmission electron microscopy image of the SF-C hemostatic sponge precursor solution, and the results show that the (211) crystal plane and the (002) crystal plane can be observed.
[0104] Figure 1 F is the XRD spectrum characterization of SF-C hemostatic sponge, SF-N hemostatic sponge and simulated calcium phosphate crystal chain. The results show that the calcium phosphate crystal chain in the SF-C hemostatic sponge contains (002), (102), (211) and (112) crystal planes, which coincide with the crystal planes contained in the simulated calcium phosphate crystals. The hydroxyapatite in the SF-N hemostatic sponge also contains (210) and (300) crystal planes, indicating that there are certain differences between the calcium phosphate crystal chains assembled and constructed in the SF-N hemostatic sponge and the traditional hydroxyapatite particles.
[0105] (3) Analysis of the bendability of the calcium phosphate crystal chains of the SF-C hemostatic sponge in Example 1:
[0106] Figure 1 G is a simulated image of a calcium phosphate crystal chain, indicating that the calcium phosphate crystal chain grows continuously along the c-axis.
[0107] Figure 1 H is a high-resolution transmission electron microscopy image of calcium phosphate crystal chains with different curvatures, indicating that the calcium phosphate crystal chains have a bending curvature of 0-73°.
[0108] Figure 1 I is the bending energy of calcium phosphate crystal chains of different thicknesses at different bending angles, combined with the fracture energy of CaP crystals to show the maximum bending angles of different crystal chains.
[0109] Figure 1 J is the relationship between the maximum bending angle and the maximum fracture energy of CaP crystal chains of different thicknesses, indicating that 1.90 nm is the critical thickness of the CaP crystal chain, and the CaP crystal chain of this thickness has both a certain bending angle and a certain bending energy.
[0110] Figure 1 The bending energy of the CaP chain with K of 1.90 nm at different bending angles, combined with the blue area, indicates that the bending energy of the CaP crystal chain is much greater than that of organic polymers.
[0111] Experimental Example 2: Performance test of the hemostatic sponge (SF-C) prepared in Example 1:
[0112] (1) Morphological observation: Figure 2 A is a macroscopic image of the hemostatic sponge (SF-C) prepared in Example 1.
[0113] (2) Mechanical tests were performed on the SF-C hemostatic sponge prepared in Example 1 and the SF-N hemostatic sponge and SF hemostatic sponge prepared in Comparative Examples 1-2:
[0114] The results are as follows Figure 2 B and Figure 2 As shown in Figure C, the compression capacity of the three sponges was tested by uniaxial compression test, and it was found that the SF-C hemostatic sponge has better mechanical strength than the SF and SF-N hemostatic sponges, and when the strain is 60%, the stress generated by the SF-C hemostatic sponge is also significantly higher than that of the SF and SF-N hemostatic sponges. Figure 2 As shown in D, the elastic modulus calculated for the SF-C hemostatic sponge is also significantly higher than that for the SF and SF-N hemostatic sponges.
[0115] (3) The liquid absorption capacity of the SF-C hemostatic sponge prepared in Example 1 and the SF-N hemostatic sponge and SF hemostatic sponge prepared in Comparative Examples 1-2 was tested:
[0116] Figure 2 E is the high-speed camera photography result of SF, SF-N and SF-C hemostatic sponges when absorbing liquid. Figure 2 As shown in Figures 2F and 2G, the deformation recovery rate and liquid absorption rate of the SF-C hemostatic sponge are significantly higher than those of the SF and SF-N hemostatic sponges, indicating that the SF-C hemostatic sponge has a better liquid absorption capacity.
[0117] (4) Testing the space filling effect of the SF-C hemostatic sponge prepared in Example 1 and the SF-N hemostatic sponge and SF hemostatic sponge prepared in Comparative Examples 1-2 in different molds:
[0118] Figure 3 A is the space filling of SF, SF-N and SF-C hemostatic sponges in a mold with smooth edges. Figure 3 As shown in B, the space filling rate of SF-C hemostatic sponge in the mold with smooth edges is significantly higher than that of SF and SF-N hemostatic sponges, indicating that SF-C hemostatic sponge has better adaptability to the mold with smooth edges.
[0119] Figure 3 C is the space filling of SF, SF-N and SF-C hemostatic sponges in a mold with sharp edges. Figure 3As shown in B, the space filling rate of SF-C hemostatic sponge in the mold with sharp edges is significantly higher than that of SF and SF-N hemostatic sponges, indicating that SF-C hemostatic sponge has better adaptability to the mold with sharp edges. Figure 3 E and 3F are optical microscope images of SF-C hemostatic sponge against a sharp-edged mold, indicating that the SF-C hemostatic sponge can well adapt to irregular areas at the 10 μm level.
[0120] Figure 3 The results showed that compared with SF and SF-N hemostatic sponges, SF-C hemostatic sponge could better adapt to irregularly shaped molds and could even fill defects smaller than 10 μm.
[0121] Experimental Example 3: Testing the hemostatic effect and safety of the hemostatic sponge (SF-C) prepared in Example 1:
[0122] (1) Test of the hemostatic effect of SF-C sponge in soft tissue injury bleeding model:
[0123] Thirty 8-week-old male Sprague Dawley rats (weighing 250-300g) were randomly divided into 6 groups to evaluate the hemostatic properties of different hemostatic materials in the rat liver penetrating injury bleeding model. The rats were anesthetized by intraperitoneal injection of 2% sodium pentobarbital at a dose of 0.2mL / 100g. The abdomen was incised after disinfection with iodine tincture, and the liver was lifted and placed on the surface of pre-weighed filter paper. Subsequently, a circular perforation wound with a diameter of 5mm was created to construct a rat liver penetrating injury bleeding model. Cylindrical SF, SF-N and SF-C hemostatic sponges with a diameter of 5.5mm were used to fill the wound, and gauze (Gauze) and gelatin sponge (GS) were used as positive controls. Schematic diagram of the hemostatic process is shown in the figure Figure 4 A. The total blood loss is calculated by measuring the total weight of the blood absorbed on the filter paper and the blood contained in the hemostatic material. When there is no significant change in the amount of blood on the filter paper, the hemostasis time is recorded.
[0124] After the excised liver tissue was removed, the wound began to bleed immediately, eventually resulting in a large amount of blood on the filter paper of the blank group. Figure 4 As shown in Figure B, the loose structure of the gauze ensures rapid blood penetration, but it cannot quickly fill the defect and provide sufficient pressure to stop bleeding. The gelatin sponge cannot absorb blood quickly and cannot effectively compress the liver defect. When the amount of blood on the filter paper does not change significantly, the hemostatic effect at this time point is as follows: Figure 4 As shown in D, the total bleeding volume of gauze or gelatin sponge in the liver penetrating injury bleeding model was 0.78±0.10g and 0.67±0.13g, respectively. Figure 4 E), the corresponding hemostasis times were 101.8±7.4s and 86.4±5.4s ( Figure 4F). Figure 4 As shown in Figure C, SF, SF-N and SF-C hemostatic sponges have higher blood absorption rate, cavity filling rate and compression force. Among them, it is worth noting that the rapid cavity filling, blood absorption rate and elastic modulus of the SF-C hemostatic sponge reinforced with critical-sized CaP crystal chains significantly improved the hemostatic effect of the liver, completely absorbed blood within 2 seconds, and the increased compression force effectively inhibited liver bleeding. Figure 4 E and Figure 4 As shown in F, after hemostasis, the total blood loss in the SF hemostatic sponge group and the SF-N hemostatic sponge group were 0.54±0.10 g and 0.53±0.10 g, respectively, and the corresponding hemostatic time was 64.6±10.5 s and 63.8±5.8 s, respectively; the hemostatic time of the SF-C hemostatic sponge group was shortened to 36.0±5.3 s, and the total blood loss was controlled at 0.16±0.06 g, which was only ≈1 / 4 of the weight of the commercially available gauze group or the GS group.
[0125] (2) Test of the hemostatic effect of SF-C hemostatic sponge in a hard tissue injury bleeding model:
[0126] Thirty 8-week-old male Sprague Dawley rats (weight 250-300g) were randomly divided into 6 groups to evaluate the hemostatic properties of different hemostatic materials in the rat tibial penetrating injury bleeding model. The rats were anesthetized by intraperitoneal injection of 2% sodium pentobarbital at a dose of 0.2mL / 100g. After disinfection with iodine, the skin at the tibia was incised, and the soft tissue was incised to fully expose the tibia. Subsequently, a circular perforation wound with a diameter of 2.3mm was created on the tibia to construct a rat tibial penetrating injury bleeding model. Cylindrical SF, SF-N and SF-C hemostatic sponges with a diameter of 2.5mm were used to fill the wound, and gauze (Gauze) and gelatin sponge (GS) were used as positive controls. The schematic diagram of the hemostatic process is shown in the figure Figure 5 A. The total blood loss was calculated by measuring the total weight of blood contained in the hemostatic material. When there was no obvious bleeding from the tibial wound, the hemostasis time was recorded.
[0127] After making a completely penetrating cylindrical wound with a diameter of 2.3 mm on the rat tibia, blood immediately gushed out from the injured area of the tibia. The bleeding of the rat tibia defect was difficult to stop by itself, and continued to ooze blood even after 600 s of injury ( Figure 5 B). The loose structure of the gauze cannot prevent blood from seeping out of the gauze, and it lacks adaptability and compression to the injured cavity ( Figure 5 C), and the hemostasis time was 257.4±30.3s ( Figure 5 I), the amount of bleeding was as high as 0.45±0.06g ( Figure 5 H). The gelatin sponge does not have the required shape adaptability and compression force, and it is difficult to effectively prevent the continuous bleeding between the material and the tissue ( Figure 5 D), and the hemostasis time was 234.4±30.6s ( Figure 5 I), total blood loss was 0.39±0.07g( Figure 5 H). The rapid blood absorption ability and compression force of the SF hemostatic sponge group and the SF-N hemostatic sponge group have reduced the bleeding between the material and the tissue to a certain extent ( Figure 5 F and Figure 5 F), blood loss was reduced to 0.22±0.05g and 0.19±0.04g ( Figure 5 H). However, the shape adaptability of SF and SF-N hemostatic sponges was insufficient, and obvious blood leakage from the gap between the sponge and the defective tibia could still be observed, which resulted in prolonged hemostasis time to 161.8±17.3s and 163.6±21.7s, respectively ( Figure 5 I). In contrast, the SF-C hemostatic sponge has excellent shape adaptability and a higher elastic modulus. After being implanted into the tibial defect cavity, the SF-C hemostatic sponge can quickly absorb blood and fill the defect, and can better adapt to the shape of the defect cavity. The blood exudation observed in the other groups was basically suppressed ( Figure 5 G), which shortened the hemostasis time to 84.2±16.0s ( Figure 5 I), the total blood loss decreased to 0.07±0.02g ( Figure 5 H), which is almost 1 / 7 of commercial gauze and 1 / 6 of commercial gelatin sponge.
[0128] (3) Toxicity evaluation of SF-C hemostatic sponge in rats:
[0129] Fifteen 8-week-old male Sprague Dawley rats (weight 250-300g) were randomly divided into three groups to evaluate the biodegradability of SF-C hemostatic sponge in rats. The rats were anesthetized by intraperitoneal injection of 2% sodium pentobarbital at a dose of 0.2mL / 100g. The back skin was incised after disinfection with iodine, and the SF-C hemostatic sponge was implanted in a 1cm incision on the back of the rats. Samples were collected on the 7th, 14th and 28th days for section staining and observation.
[0130] Ten 8-week-old male Sprague Dawley rats (weight 250-300g) were randomly divided into two groups to evaluate the biocompatibility of SF-C hemostatic sponge in rats. The rats were anesthetized by intraperitoneal injection of 2% sodium pentobarbital at a dose of 0.2mL / 100g. The back skin was incised after disinfection with iodine tincture, and the SF-C hemostatic sponge was implanted in a 1cm incision on the back of the rats. On the 28th day, the main organs of the rats were collected for section staining and observation, and blood samples were tested for blood routine and liver function tests.
[0131] like Figure 6As shown in A, the SF-C hemostatic sponge was almost completely degraded after 28 hours of subcutaneous implantation. Figure 6 As shown in BG, the degradation products had no significant effects on the main organs, blood routine and liver function of rats, reflecting good biodegradability and biocompatibility.
[0132] Experimental Example 4: Testing the mechanical properties, liquid absorption properties and hemostatic properties of the hemostatic sponge (SF-LC) prepared in Example 2
[0133] (1) Mechanical tests were performed on the SF-LC hemostatic sponge prepared in Example 2 and the SF sponge prepared in Comparative Example 2:
[0134] The results are as follows Figure 7 As shown in A, when the strain is 60%, the stress generated by the SF-LC sponge is significantly higher than that of the SF hemostatic sponge. Figure 7 As shown in B, the elastic modulus calculated by SF-LC hemostatic sponge is also significantly higher than that of SF hemostatic sponge. These results indicate that SF-LC hemostatic sponge has better mechanical properties than SF hemostatic sponge.
[0135] (2) The liquid absorption performance of the SF-LC hemostatic sponge prepared in Example 2 and the SF hemostatic sponge prepared in Comparative Example 2 was tested:
[0136] The results are as follows Figure 7 As shown in C and 7D, the deformation recovery rate and liquid absorption rate of SF-LC hemostatic sponge are significantly higher than those of SF hemostatic sponge, indicating that SF-LC hemostatic sponge has better liquid absorption capacity than SF hemostatic sponge.
[0137] (3) Comparison of the hemostatic performance of the SF-LC hemostatic sponge prepared in Example 2 and the SF hemostatic sponge prepared in Comparative Example 2 in a soft tissue injury bleeding model:
[0138] Figure 7 E and 7F are macroscopic images of SF and SF-LC hemostatic sponges used to stop bleeding in soft tissue injuries. Figure 7 As shown in G and 7H, the SF-LC hemostatic sponge has less bleeding volume and shorter bleeding time, indicating that the SF-LC hemostatic sponge has a better hemostatic effect in soft tissue injury bleeding than the SF hemostatic sponge.
[0139] (4) Comparison of the hemostatic performance of the SF-LC hemostatic sponge prepared in Example 2 and the SF hemostatic sponge prepared in Comparative Example 2 in a hard tissue injury bleeding model:
[0140] Figure 7 I and 7J are macroscopic images of SF and SF-LC hemostatic sponges used to stop bleeding in hard tissue injuries. Figure 7As shown in K and 7L, the SF-LC hemostatic sponge has less bleeding volume and shorter bleeding time, indicating that the SF-LC hemostatic sponge has a better hemostatic effect in hard tissue injury bleeding than the SF hemostatic sponge.
[0141] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention is described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A method for preparing a hemostatic sponge for complex tissue damage, characterized in that: The following steps are involved: (1) boiling the washed silk cocoons with a sodium carbonate solution for degumming; (2) dissolving the silkworm cocoons treated in step (1) in a lithium bromide solution, dialyzing for desalination, then centrifuging and discarding the precipitate, and heating and concentrating the supernatant to obtain a silk fibroin solution; (3) adding triethylamine to the ethanol solution of calcium chloride under stirring, then dropping the ethanol solution of phosphoric acid, centrifuging, and resuspending with ethanol to obtain a calcium phosphate oligomer solution; (4) centrifuging the calcium phosphate oligomer solution obtained in step (3), washing, resuspending, and evenly mixing with the silk fibroin solution obtained in step (2), and incubating at room temperature to obtain a hemostatic sponge precursor solution; (5) The hemostatic sponge precursor solution obtained in step (4) is frozen, annealed at low temperature, thawed at room temperature, then freeze-dried, and sterilized by irradiation to obtain a hemostatic sponge for complex tissue damage.
2. The method for preparing a hemostatic sponge for complex tissue damage according to claim 1, characterized in that: In step (1), the bath ratio of the silkworm cocoons to the sodium carbonate solution is 10:2-3 g / L, and the concentration of the sodium carbonate solution is 0.01-0.03M.
3. The method for preparing a hemostatic sponge for complex tissue damage according to claim 1, characterized in that: In step (2), the bath ratio of the treated silkworm cocoons to the lithium bromide solution is 2:10-15 g / mL, and the concentration of the lithium bromide solution is 9-10 M.
4. The method for preparing a hemostatic sponge for complex tissue damage according to claim 1, characterized in that: In step (2), the concentration of the silk fibroin solution is 80-100 mg / mL.
5. The method for preparing the hemostatic sponge for complex tissue damage according to claim 1, characterized in that: In step (3), the molar ratio of phosphoric acid to calcium chloride is 3:3-5.
6. The method for preparing the hemostatic sponge for complex tissue damage according to claim 1, characterized in that: In step (3), the concentration of the calcium phosphate oligomer solution is 4-6 mg / mL.
7. The method for preparing a hemostatic sponge for complex tissue damage according to claim 1, characterized in that: In step (4), in the hemostatic sponge precursor solution, the mass ratio of the calcium phosphate oligomer to the silk fibroin is 1:4-15.
8. The method for preparing the hemostatic sponge for complex tissue damage according to claim 1, characterized in that: In step (5), the low-temperature annealing temperature is -4 to -8°C and the time is 24-72 hours.
9. A hemostatic sponge for complex tissue damage prepared according to the preparation method according to any one of claims 1 to 8.
10. Use of the hemostatic sponge according to claim 9 in preparing hemostatic materials for soft and hard tissue injuries.
